CORT Financial Facts

Basic and diluted net loss per share: 0.02
Research and development: 4.09M
See Full Income Statement

Total current assets: -85.08M
Prepaid expenses and other current assets: -2.4M
See Full Balance Sheet

Corcept Therapeutics (CORT) Earnings

  |   Expand Research on CORT
Next EPS Date 5/6/16 *Est. EPS Growth Rate +150.0% *Last Qtr.
Average EPS % Beat Rate +56.3% Revenue Growth Rate +66.5% *Last Qtr.
Average % Move 1-Wk after EPS +8.2% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
1/28/16 Q415 $0.01-$0.02 +$0.03$15M$15.5M = Details
11/5/15 Q315 -$0.01-$0.02 +$0.01$13.3M$13.9M N/A Details
8/5/15 Q215 -$0.02-$0.04 +$0.02$12M$11.67M N/A Details
5/7/15 Q115 -$0.05-$0.04 -$0.01$10.1M$10.5M N/A Details
3/4/15 Q414 -$0.02-$0.06 +$0.04$9.01M$9.1M N/A Details
11/4/14 Q214 N/A-$0.07 N/A N/A$7.62M N/A N/A N/A
5/7/14 Q114 -$0.11-$0.09 -$0.02$4.41M$5.01M N/A Details
3/5/14 Q413 -$0.11-$0.10 -$0.01$4.1M$4.01M N/A Details